Showing results (61-70 of 100) with videos related to
Sort By:
Pageof 10
The Oncologist|June 23, 2025
Long-term survival in advanced unresectable HCC treated with transcatheter arterial chemoembolization combined with lenvatinib and PD-1 inhibitorsZhen-Xin Zeng, Hua-Chun Song, Yi-Nan Li, et al.Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|May 25, 2021
Tislelizumab Plus Chemotherapy as First-Line Treatment for Locally Advanced or Metastatic Nonsquamous NSCLC (RATIONALE 304): A Randomized Phase 3 TrialShun Lu, Jie Wang, Yan Yu, et al.Cancer Medicine|May 21, 2024
The effect of liver metastases on clinical efficacy of first-line programmed death-1 inhibitor plus chemotherapy in esophageal squamous cell carcinoma: A post hoc analysis of ASTRUM-007 and meta-analysisJing Gao, Yan Song, Xiaoge Kou, et al.The Lancet. Respiratory Medicine|June 13, 2024
Garsorasib in patients with KRASG12C-mutated non-small-cell lung cancer in China: an open-label, multicentre, single-arm, phase 2 trialZiming Li, Xiaomin Dang, Dingzhi Huang, et al.Nature Medicine|February 2, 2023
First-line serplulimab or placebo plus chemotherapy in PD-L1-positive esophageal squamous cell carcinoma: a randomized, double-blind phase 3 trialYan Song, Bo Zhang, Dao Xin, et al.Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|March 22, 2023
D-1553 (Garsorasib), a Potent and Selective Inhibitor of KRASG12C in Patients With NSCLC: Phase 1 Study ResultsZiming Li, Zhengbo Song, Yanqiu Zhao, et al.Nature Communications|June 12, 2023
Phase 1b trial of anti-EGFR antibody JMT101 and Osimertinib in EGFR exon 20 insertion-positive non-small-cell lung cancerShen Zhao, Wu Zhuang, Baohui Han, et al.The Lancet. Respiratory Medicine|December 7, 2025
First-line serplulimab plus chemotherapy with or without HLX04 versus chemotherapy in locally advanced or metastatic non-squamous non-small-cell lung cancer (ASTRUM-002): a randomised, double-blind, multicentre phase 3 trialLin Wang, Xuezhi Hao, Yanrong Hao, et al.Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|August 10, 2024
Efficacy and Safety of KRASG12C Inhibitor IBI351 Monotherapy in Patients With Advanced NSCLC: Results From a Phase 2 Pivotal StudyQing Zhou, Xiangjiao Meng, Longhua Sun, et al.Journal of Thoracic Disease|July 13, 2018
TP53 mutations predict for poor survival in ALK rearrangement lung adenocarcinoma patients treated with crizotinibWen-Xian Wang, Chun-Wei Xu, Yan-Ping Chen, et al.Pageof 10